文献速递中医内科中药与中成药合理使用

艾迪注射液用于肿瘤治疗的系统评价再评价

Chinese patent medicine Aidi injection for cancer care: An overview of systematic reviews and meta-analyses.
PubMed 文献 · J Ethnopharmacol · 2021-09-20

艾迪注射液在生存、客观缓解率、生活质量和减轻放化疗副作用方面显示额外获益,但方法学和报告质量普遍偏低。

要点

  • 艾迪注射液辅助治疗在肺癌、肝癌和结直肠癌中研究最多。
  • 多数系统评价显示艾迪注射液联合化疗/放疗可改善生存、疗效和生活质量。
  • 纳入系统评价的方法学质量多为极低,主要因缺乏前瞻性注册。

核心结论

  • 艾迪注射液作为辅助治疗在肿瘤生存、肿瘤缓解、生活质量及减轻放化疗副作用方面显示出有益作用,但证据的方法学和报告质量薄弱。

主要发现

  • 除1篇关注艾迪注射液单用外,其余评价艾迪注射液联合化疗43篇、放疗4篇、化/放/靶向治疗4篇。
  • 艾迪注射液在生存(9篇)、客观缓解率(44篇)、生活质量(42篇)和减少放化疗副作用(48篇)方面显示额外有益效果。

关键数值与推荐

  • 采用AMSTAR 2评估,2篇系统评价为低质量,其余为极低质量,主要因缺乏前瞻性注册。
  • 采用PRISMA评估报告质量不足,检索策略报告26篇(50.0%)、附加分析报告19篇(36.5%)、证据总结报告2篇(3.8%)。

临床怎么用

  • 艾迪注射液作为辅助治疗可用于肺癌、肝癌和结直肠癌等,可能改善生存、肿瘤缓解和生活质量并减轻放化疗副作用,但需结合低质量证据谨慎决策。

局限性

  • 纳入系统评价的方法学质量多为极低,报告质量不足,主要缺陷包括缺乏前瞻性注册和检索策略等报告不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Aidi injection is one of the China Food and Drug Administration approved Chinese herbal injections and the most competitive product in cancer care in China. It is composed of the extracts from Mylabris Phalerata, Astragalus Membranaceus, Panax Ginseng, and Acanthopanax Senticosus. AIM OF THE STUDY: This overview aims to map systematic reviews (SRs) of Aidi injection for cancer and provide a summarized evidence for clinical practice and decision making. MATERIALS AND METHODS: Seven databases were searched for SRs and/or meta-analyses of randomized controlled trials on Aidi injection for cancer care until December 2020. Six authors worked in pairs independently identified studies, collected data, and assessed the quality of included studies according to the revised Assessment of Multiple Systematic Reviews (AMSTAR 2) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A narrative synthesis was used for the evidence mapping. RESULTS: Fifty-two SRs on Aidi injection as adjuvant therapy were included, involving lung cancer (20 SRs), liver cancer (10), colorectal cancer (7), gastric cancer (6), lymphoma (2), breast cancer (2), esophageal cancer (1), ovary cancer (1), and a mix of different cancers (4). Except for one SR focusing on Aidi injection used alone, other SRs evaluated Aidi injection in combination with chemotherapy (43), radiotherapy (4), or chemo/radiology/targeting therapy (4). Aidi injection showed additional beneficial effects on survival (9), objective response rate (44), quality of life (42), and the reduction of side-effects from chemo/radiotherapy (48). Using AMSTAR 2 tool, two reviews were assessed as low and the rest as critically low methodological quality mainly due to the lack of prospective registration. The reporting quality was insufficient assessed with PRISMA in the reporting of search strategy (26, 50.0%), additional analysis (19, 36.5%), and the summary of evidence (2, 3.8%). CONCLUSION: Aidi injection has been evaluated for its adjuvant beneficial effects on cancer survival, tumor responses, quality of life, and reducing the side effects of chemo/radiotherapy, mainly focusing on lung, liver and colorectal cancer. The methodological and reporting quality are weak and need to be improved in the future.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Yang M, Shen C, Zhu SJ, et al. Chinese patent medicine Aidi injection for cancer care: An overview of systematic reviews and meta-analyses. J Ethnopharmacol. 2021. PMID: 34551361. doi:10.1016/j.jep.2021.114656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。